Extrinsic and Intrinsic Factors in Atopic Dermatitis Upon Systemic Immune Modulation
Recruiting · NCT05098821 · Observational (researchers observe without assigning treatment) · Lead sponsor: Charite University, Berlin, Germany
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
Currently, patients with moderate to severe atopic dermatitis are treated with dupilumab if unresponsive to topical treatment. However, not all patients who suffer from atopic dermatitis respond similarly to this treatment. Pattern recognition of immune cells (PRI) is an efficient method to screen patients to allow a more personalized therapy. The main aim of this scientific explorative study is to unravel the changes in peripheral blood immune cell compositions in patients with atopic eczema undergoing dupilumab treatment. This allows the identification of phenotypes of treatment responders and non-responders and possible approaches of treatment modifications for non-responders.
Who can take part
Inclusion criteria
- Age 18 and above
- Diagnosis of atopic dermatitis for ≥1 year
- Inadequate response to treatment with topical medications
- Confirmed dupilumab treatment
Exclusion criteria
- Age below 18
- Known or suspected allergy or reaction to any component of the dupilumab formulation
- Known active allergic or irritant contact dermatitis that is likely to interfere with the assessment of the severity of AD
- Severe conjunctivitis or blepharitis
Where it is running
1 location listed.
- Dpt of Dermatology and Allergology, Charité - Universitätsmedizin Berlin - Berlin, Germany